Last updated: June 1, 2026
CETIRIZINE HYDROCHLORIDE (HIVES): Who supplies the active ingredient, branded finished product, and key intermediates?
Cetirizine hydrochloride for hives (chronic urticaria and allergic conditions) is supplied through a typical multi-tier value chain: API producers, intermediate makers (not always visible publicly), and finished-dose manufacturers for tablets/capsules/syrup/drops. Brand and generic supply are fragmented across geographies, with product labels most reliably showing the final NDA holder (or marketer) and the manufacturing sites, while the upstream API and key intermediates are often sourced from multiple suppliers.
What companies supply cetirizine hydrochloride API for tablets and syrups?
API supply for cetirizine hydrochloride is dominated by global chemical manufacturers that also sell intermediates and/or contract-manufacture finished dosages. Publicly visible supplier lists tend to come from:
- Drug master files (DMFs) that support ANDAs
- Exhibit listings in regulatory submissions
- Labeler information on finished products
- Import/export and procurement documentation (where disclosed)
Common API supplier countries for cetirizine hydrochloride include India, China, and several EU/EEA chemical hubs. In practice, multiple API makers supply the same generic ANDA through DMF cross-licenses and co-sourcing strategies.
Which dosage forms drive cetirizine supplier demand (hives indication)?
- Tablets (typically 10 mg)
- Syrup (typical 5 mg/5 mL)
- Drops (typical mg/mL strength depends on jurisdiction)
- Pediatric formulations (leading to more SKU fragmentation and secondary packaging requirements)
Why supplier selection differs by dosage form
- Syrup and drops add solubility, viscosity, and preservative system constraints that can change the approved manufacturing process.
- Tablets emphasize compression and coating properties and may involve different granulation approaches even with the same API supplier.
Who supplies cetirizine hydrochloride finished dosage products for hives in the US?
For “hives” use cases, US market supply is split between:
- Branded products marketed under cetirizine hydrochloride label claims
- Generic tablets, syrups, and drops marketed under ANDAs
Finished-dose “suppliers” in the US are best identified by labeler/marketer and the listed manufacturer(s) on the package insert or label (often different from the API DMF holder). Generic supply changes quickly as ANDAs gain or lose market share.
Typical US supply structure
- Marketer/labeler (ANDA holder)
- Finished-dose manufacturer (contract sites listed in labeling or application records)
- API DMF holder (upstream API supplier, not always the same as finished-dose manufacturer)
What patents or exclusivity affect cetirizine hydrochloride supply and entry?
Cetirizine hydrochloride is an established antihistamine with long market history. Most current US generics are not constrained by first-entry exclusivity, and supply is usually governed by:
- Patent estates on specific formulations (if any exist for certain dosage technologies)
- Process patents (rarely decisive for broad access unless actively enforced)
- Orange Book listings and any active Hatch-Waxman litigation tied to particular ANDAs
How exclusivity timelines typically shape generic competition
- New pediatric exclusivity, formulation exclusivity, or switching to a new dosage form can delay some launches.
- Older method-of-use or formulation patents, if any remain active in certain jurisdictions, can affect entry for specific strengths or delivery systems.
What generic entry risks exist for cetirizine hydrochloride hives products?
For an established drug, entry risks usually concentrate in:
- Manufacturing compliance risk (GMP, remediation history, batch consistency)
- Bioequivalence / performance risk for specific dosage forms (especially liquid)
- Regulatory risk tied to chemistry/manufacturing controls (CMC comparability)
- Litigation risk tied to Orange Book listings for specific ANDAs (low likelihood for cetirizine core products but can occur around particular strengths/dosage forms)
Where risk is most concentrated
- OTC switches and labeling changes (if formulation or excipient systems differ)
- Different salt/hydrate control strategies if sources or processes change
- Pediatric liquid approvals where stability data and preservative systems matter
How strong is the patent estate for cetirizine hydrochloride (hives indication)?
Core cetirizine hydrochloride API patents from early development are historically far expired in most major markets, so the practical barrier is rarely API composition patents. The remaining IP risk typically comes from:
- Specific formulation patents (certain excipient blends, coatings, release control, or combination products)
- Device or dosing system patents for newer delivery formats
- Any still-active process patents that a particular NDA/ANDA relies on
Which suppliers produce cetirizine dihydrochloride vs cetirizine hydrochloride?
For OTC and prescription hives treatment, market formulations overwhelmingly use cetirizine hydrochloride. A minority of markets may reference different salt forms in scientific literature, but commercial supply for hives is typically the hydrochloride.
How do cetirizine hydrochloride supply chains differ between API-only suppliers and finished-dose manufacturers?
API suppliers supply bulk cetirizine hydrochloride meeting DMF specifications.
Finished-dose manufacturers buy API (often through multiple sources) and execute:
- Blending and granulation
- Tableting/capsule filling
- Liquid compounding with excipient and preservative system integration
- Packaging and labeling validation for regional requirements
Practical implications for procurement
- If you are sourcing finished doses, supplier qualification must include both API traceability and the finished-dose site’s GMP record.
- If you are sourcing API, specification control, polymorph/hydrate form controls, and impurity profiles become the deciding factors.
What are the leading global procurement regions for cetirizine hydrochloride?
Procurement typically concentrates in:
- India: strong generic finished-dose ecosystem; active chemical manufacturing base
- China: large-scale API chemical supply
- EU/UK (smaller share): often as formulation or packaging sites rather than bulk API for widely generic drugs
Key supplier map for cetirizine hydrochloride hives products (how to verify in practice)
Because cetirizine hydrochloride is widely generic, the reliable “supplier map” must be built from label and regulatory records rather than third-party supplier lists. The verification workflow for procurement or competitive intelligence is:
- Identify the ANDA holder/labeler on the product packaging.
- Confirm finished-dose manufacturer(s) listed in labeling.
- Trace API DMF reference through Orange Book/ANDA documents (where accessible).
- Cross-check impurity profiles and specification acceptance in purchasing documents.
Data structures procurement teams actually use
- Product strength and dosage form (tablet/syrup/drops)
- Labeler/ANDA holder
- Finished-dose site(s) and lot release model
- API DMF number or supplier designation (when disclosed)
- Certificate of Analysis and impurity limits
- Supply reliability metrics (lead time, MOQ, batch disposition history)
Key Takeaways
- Cetirizine hydrochloride for hives is supplied via a mature generic ecosystem with multiple API and finished-dose manufacturers.
- Finished-dose “suppliers” are identified by labeler/ANDA holder and manufacturing sites listed on product labeling, while API supplier identity is often tied to DMFs.
- Supply and entry risk are typically driven by CMC compliance, bioequivalence for liquid/tablet performance, and any specific formulation patents tied to certain dosage forms, not by core cetirizine composition IP.
FAQs
-
How can I identify the API supplier behind a cetirizine hydrochloride generic bottle?
Use DMF references in the ANDA record and cross-check against labeling for the finished-dose manufacturer.
-
Which cetirizine hydrochloride dosage form has the highest manufacturing variability risk (tablet vs syrup)?
Liquid formulations typically carry higher variability risk due to preservative and stability constraints.
-
Do cetirizine hydrochloride products for chronic urticaria differ in formulation from typical allergy tablets?
They usually share the same API and strength range, but excipient systems and regulatory labeling differences can vary by brand/ANDA.
-
What regulatory pathway is most common for generic cetirizine hydrochloride hives products?
ANDA for oral dosage forms; OTC and branded variations may use different labeling frameworks but still rely on established generic quality standards.
-
Are there still active patents that can delay cetirizine hydrochloride generics in major markets?
Broad core API patents are generally expired; remaining delays, if any, usually relate to specific formulation/process or dosage-form claims tied to certain ANDAs.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA Drugs@FDA. U.S. Food and Drug Administration.
